What is the current valuation of the US anti-fungal treatment market?

As of 2024, the US anti-fungal treatment market was valued at 3.15 USD Billion. Read More

What is the projected market size for the US anti-fungal treatment market by 2035?

The market is projected to reach 4.8 USD Billion by 2035. Read More

What is the expected CAGR for the US anti-fungal treatment market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 3.89%. Read More

Which companies are the key players in the US anti-fungal treatment market?

Key players include Pfizer Inc, Bristol-Myers Squibb Company, Merck & Co., Inc., and Gilead Sciences, Inc. Read More

How are dermatological infections performing in the market?

Dermatological infections generated approximately 1.4 USD Billion in 2024 and are expected to grow. Read More

What is the market size for systemic infections in the US anti-fungal treatment market?

Systemic infections accounted for about 1.8 USD Billion in 2024. Read More

Which drug types are leading in the US anti-fungal treatment market?

Azoles are leading with a market size of 1.8 USD Billion in 2024. Read More

What is the market performance for oral administration routes in the US anti-fungal treatment market?

Oral administration routes reached 1.8 USD Billion in 2024 and are anticipated to grow. Read More

How does the market for geriatric patients compare to other demographics?

The geriatric segment was valued at 1.2 USD Billion in 2024, indicating a growing need. Read More

What trends are observed in the US anti-fungal treatment market by application?

By application, systemic infections and dermatological infections are expected to show notable growth. Read More

Antifungal Treatment Market

ID: MRFR/HC/17148-HCR

100 Pages

Garvit Vyas

Last Updated: April 06, 2026

US Anti-Fungal Treatment Market Research Report: Size, Share, Trend Analysis - Growth Outlook & Industry Forecast 2025 To 2035

US Anti-Fungal Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Dermatological Infections
  2. 4.1.2 Systemic Infections
  3. 4.1.3 Ocular Infections
  4. 4.1.4 Oral Infections
2. 4.2 Healthcare, BY Drug Type (USD Billion)
  1. 4.2.1 Azoles
  2. 4.2.2 Echinocandins
  3. 4.2.3 Polyenes
  4. 4.2.4 Allylamines
3. 4.3 Healthcare, BY Route of Administration (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Topical
  3. 4.3.3 Intravenous
  4. 4.3.4 Inhalation
4. 4.4 Healthcare, BY Patient Demographics (USD Billion)
  1. 4.4.1 Pediatric
  2. 4.4.2 Adult
  3. 4.4.3 Geriatric
  4. 4.4.4 Immunocompromised
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co., Inc. (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences, Inc. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Johnson & Johnson (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Astellas Pharma Inc. (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie Inc. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GlaxoSmithKline plc (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY DRUG TYPE
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
14. 6.14 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
16. 6.16 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
18. 6.18 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY DRUG TYPE, 2026-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2022-2035)

Dermatological Infections
Systemic Infections
Ocular Infections
Oral Infections

Healthcare By Drug Type (USD Billion, 2022-2035)

Azoles
Echinocandins
Polyenes
Allylamines

Healthcare By Route of Administration (USD Billion, 2022-2035)

Oral
Topical
Intravenous
Inhalation

Healthcare By Patient Demographics (USD Billion, 2022-2035)

Pediatric
Adult
Geriatric
Immunocompromised

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”